Sahajanand Medical Technologies
Developer and manufacturer of minimally invasive cardiovascular devices including coronary drug-eluting stents, balloon dilatation catheters, transcatheter aortic valve systems and structural heart occluders. The company develops biodegradable polymer coating formulations for controlled drug release on stent platforms, conducts clinical studies and registries, pursues international regulatory approvals, and maintains global distribution and tender participation.
Industries
Nr. of Employees
large (251-1000)
Sahajanand Medical Technologies
Patents
Bioresorbable vascular implant having homogenously distributed stresses under a radial load
US-9566177-B2
View Details
Bioresorbable vascular implant having homogenously distributed stresses under a radial load
US-9566177-B2
View DetailsProducts
Coronary sirolimus-eluting stent (biodegradable polymer coating)
Coronary drug-eluting stent platform using a biodegradable multi-layer polymer matrix for controlled sirolimus release and engineered scaffold/link geometry for deliverability.
Coronary everolimus-eluting stent (thin biodegradable coating)
Everolimus-eluting coronary stent with a thin biodegradable polymer coating intended to inhibit neointimal hyperplasia and provide favorable handling characteristics.
Coronary sirolimus-eluting stent (uniform scaffolding design)
Sirolimus-eluting stent with scaffold design metrics intended for uniform drug distribution and enhanced apposition in tortuous anatomy.
Transcatheter aortic valve replacement (TAVR) system
Self-expanding transcatheter aortic valve system for treatment of aortic stenosis, subject to clinical evaluation and regulatory approvals.
Semi-compliant and non-compliant PTCA balloon catheters
Range of PTCA balloon catheters (semi-compliant and non-compliant) with multi-layer polyamide balloons, selective hydrophilic coating, low tip entry profile and defined compliance and burst pressure characteristics across multiple diameters and lengths.
Structural heart occluder devices (septal, PFO, duct, VSD)
Portfolio of occluder devices intended for closure of congenital and structural intracardiac defects.
Coronary sirolimus-eluting stent (biodegradable polymer coating)
Coronary drug-eluting stent platform using a biodegradable multi-layer polymer matrix for controlled sirolimus release and engineered scaffold/link geometry for deliverability.
Coronary everolimus-eluting stent (thin biodegradable coating)
Everolimus-eluting coronary stent with a thin biodegradable polymer coating intended to inhibit neointimal hyperplasia and provide favorable handling characteristics.
Coronary sirolimus-eluting stent (uniform scaffolding design)
Sirolimus-eluting stent with scaffold design metrics intended for uniform drug distribution and enhanced apposition in tortuous anatomy.
Transcatheter aortic valve replacement (TAVR) system
Self-expanding transcatheter aortic valve system for treatment of aortic stenosis, subject to clinical evaluation and regulatory approvals.
Semi-compliant and non-compliant PTCA balloon catheters
Range of PTCA balloon catheters (semi-compliant and non-compliant) with multi-layer polyamide balloons, selective hydrophilic coating, low tip entry profile and defined compliance and burst pressure characteristics across multiple diameters and lengths.
Structural heart occluder devices (septal, PFO, duct, VSD)
Portfolio of occluder devices intended for closure of congenital and structural intracardiac defects.
Services
Design and execution support for randomized trials and multicenter registries evaluating interventional cardiovascular devices.
In-house regulatory affairs and quality systems management to support submissions and global compliance.
Manufacture and supply of stents, balloon catheters and interventional accessories in CE-approved sizes and SKUs.
Design and execution support for randomized trials and multicenter registries evaluating interventional cardiovascular devices.
In-house regulatory affairs and quality systems management to support submissions and global compliance.
Manufacture and supply of stents, balloon catheters and interventional accessories in CE-approved sizes and SKUs.
Expertise Areas
- Clinical trial management and registries
- Drug-eluting stent platform development and polymer coating formulation
- Balloon catheter and rapid-exchange shaft engineering
- Transcatheter aortic valve systems
Key Technologies
- Biodegradable polymer coating matrices
- Drug-eluting stent platforms
- Transcatheter aortic valve technology
- Multi-layer polyamide balloon membranes
News & Updates
CE Mark approval for transcatheter aortic valve system for treatment of aortic stenosis.
Regulatory approval in Singapore for the company's transcatheter aortic valve system.
Registry results demonstrating stent performance published in BMJ Open.
Regulatory approval from the Australian Therapeutic Goods Administration for a coronary drug-eluting stent.
CE Mark awarded for the transcatheter aortic valve replacement system.
Recognition from Government of India for contributions in science and technology.
CE Mark approval for transcatheter aortic valve system for treatment of aortic stenosis.
Regulatory approval in Singapore for the company's transcatheter aortic valve system.
Registry results demonstrating stent performance published in BMJ Open.
Regulatory approval from the Australian Therapeutic Goods Administration for a coronary drug-eluting stent.
CE Mark awarded for the transcatheter aortic valve replacement system.
Recognition from Government of India for contributions in science and technology.